CT screening for lung cancer
- Schools of Biological Sciences and Health Sciences, University of Auckland, Auckland, New Zealand
- Correspondence to Dr Robert P Young, Director, Respiratory Genetics Group, Schools of Biological Sciences and Health Sciences, University of Auckland, PO Box 26161, Epsom 1344, Auckland, New Zealand; roberty{at}adhb.govt.nz
-
Contributors RPY wrote and researched the letter. RJH wrote, edited and researched the letter.
- Accepted 22 August 2011
- Published Online First 13 September 2011
We read with interest the recent opinion piece by Field et al1 outlining plans for a CT screening trial in the United Kingdom (the UK Lung Screen (UKLS)) following the results of the National Lung Cancer Screening Trial. We agree that cost-effectiveness and defining who would most likely benefit from CT screening remain key issues to be resolved before CT screening can be offered routinely in clinical practice.2
First, cost-effectiveness is most likely to be achieved through optimising the risk assessment of those potentially eligible for CT …
